Earlier today, Certara released financial results for the full year ended December 31, 2025. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings press release available on the company's website. Agencies are providing clear guidance that advances Model-Informed and computational approaches and are actively encouraging the use of new approach methodologies to modernize drug development. At the same time, we have not sufficiently converted that credibility into the level of growth the opportunity warrants, and that I believe we should and can deliver.
In fact, over time, Certara's business should be able to drive double-digit growth. Let me address the market acceptance point, and then I'll return to discuss planned operational improvements. While Certara continues to benefit from a strong legacy as a market-leading software provider, it is clear that we must sharpen our execution to fully capture the opportunity ahead of us. Despite stepping up our R&D investment in product enhancements and new products, we have not yet converted that investment into sustained organic growth.
Our specialized services address our customers' needs and advance their goals, delivering value both independently and in combination with our software. Certara's tech-enabled services continue to be a core part of our growth strategy and a critical enabler of MIDD adoption. When our consultants deploy our software and customer engagement, it surfaces new use cases and builds stickier customer relationships. Certara grows faster when our software products are integrated with our scientific expertise.